Therapeutics: Tumor necrosis factor ligand superfamily member 14 (TNFSF14; LIGHT; CD258); epidermal growth factor receptor (EGFR); programmed cell death 1 ligan

Cancer

INDICATION: Cancer

Mouse studies suggest a TNFSF14-anti-EGFR antibody fusion protein could help treat tumors resistant to

Read the full 157 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE